NEW YORK (TheStreet) --TheStreet's Jim Cramer answers Twitter (TWTR) questions from the floor of the New York Stock Exchange, and this week's first question asks what is the best spinoff to buy in 2015.
Cramer replies that he expects good things from several spinoffs, but he selects WhiteWave Foods (WWAV) , a spinoff of Dean Foods (DF) that he says still has a lot of room to run because companies such as Kellogg (K) and Kraft Foods (KRFT) are getting some more life now. He says a Kraft acquisition of WhiteWave would make a lot of sense.
The next question asks if Gilead Sciences (GILD) is overdone at $97, and Cramer says that while he has been behind Gilead (along with Regeneron (REGN) , Biogen Idec (BIIB) , and Celgene (CELG) ), he now needs to wait because it is time to reassess after the large gains there.
Cramer points to TheStreet's Adam Feuerstein's article, in which he says the Express Scripts (ESRX) hepatitis C pharmacy deal with AbbVie (ABBV) could be a game-changer. Therefore, Cramer plans to wait and see how this develops.